Skip to main content

Table 3 Incidence rate per 100 patient-years and incidence rate ratio of hospitalized infection

From: Unincreased risk of hospitalized infection under targeted therapies versus methotrexate in elderly patients with rheumatoid arthritis: a retrospective cohort study

  Young (14,668.59 PY) Elderly (10,611.63 PY) Older elderly (7,911.10 PY)
Number of HIs 473 534 804
Overall IR [95% CI] 3.20 [2.92–3.50] 4.99 [4.58–5.43] 10.14 [9.45–10.85]
IRR [95% CI] (vs. young) Reference 1.56 [1.38–1.77] 3.17 [2.83–3.55]
IR [95% CI] during exposure to MTX 2.34 [2.03–2.69] 4.90 [4.39–5.46] 11.0 [10.1–12.0]
IR [95% CI] during exposure to bDMARDs/JAKIs 4.33 [3.84–4.87] 5.12 [4.47–5.86] 8.74 [7.75-–9.82]
IRR [95% CI] (bDMARDs/JAKIs vs. MTX) 1.85 [1.54–2.22] 1.05 [0.88–1.24] 0.79 [0.68–0.92]
  1. bDMARDs Biological disease-modifying antirheumatic drugs, CI Confidence interval, IR Incidence rate, IRR Incidence rate ratio, JAKIs Janus kinase inhibitors, MTX Methotrexate, PY Patient-year